VivoSeq
Psychiatry

Cannabis Dependence

37

Pipeline Programs↗

1

Active Trials↗

23

Companies Involved↗

Cannabis Dependence is a moderately active landscape with 37 programs across 23 companies. The most active players are Eisai, Promius Pharma, LLC, Boehringer Ingelheim. 19 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

6/100

Mech. Concentration

7/100

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 1P

Promius Pharma, LLC

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 2M

Map77

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Completed11 · 79%
Unknown status1 · 7%
Terminated1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study
Not yet recruiting·RRoswell Park Cancer Institute·Phase 1·NCT06334016·60 enrolled
Atomoxetine for the Treatment of Cannabis Dependence
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00167297·16 enrolled
Study of Quetiapine Treatment for Cannabis Dependence
Completed·NNew York State Psychiatric Institute·Phase 2·NCT00954681·15 enrolled
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Completed·TThe Scripps Research Institute·Phase 2·NCT00656487·66 enrolled
Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
Completed·CCentre for Addiction and Mental Health·Phase 2·NCT01747850·45 enrolled
Quetiapine Pharmacotherapy for Cannabis Dependence
Completed·NNew York State Psychiatric Institute·Phase 2·NCT01697709·130 enrolled
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence
Completed·NNew York State Psychiatric Institute·Phase 1·NCT01467999·22 enrolled
Gabapentin Treatment of Cannabis Dependence
Completed·TThe Scripps Research Institute·Phase 2·NCT00395044·50 enrolled
Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence
Completed·MMclean Hospital·Phase 2·NCT01292642·12 enrolled
Nabilone for Cannabis Dependence: A Pilot Study
Completed·MMclean Hospital·Phase 2/3·NCT01347762·84 enrolled
Gabapentin Treatment of Cannabis Dependence
Completed·TThe Scripps Research Institute·Phase 2·NCT00974376·150 enrolled
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
Completed·NNew York State Psychiatric Institute·Phase 1/2·NCT02088177·12 enrolled
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Terminated·MMclean Hospital·Phase 2/3·NCT01598896·12 enrolled
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
Unknown status·UUniversitair Ziekenhuis Brussel·Phase 4·NCT03221231·75 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)